Injective Staking ETF Goes Live on Nasdaq: What It Means for INJ

The Injective Staking ETF has officially gone live on Nasdaq, giving investors a regulated way to gain exposure to INJ with staking rewards built in. The Canary Staked INJ ETF (ticker INJC) began trading on November 5, 2026, marking the first U.S.-listed fund focused on staked INJ and opening a clearer path for institutional interest in the Injective token.

This article explains how the INJ staking ETF works, what the numbers show so far, and what it could mean for INJ.

Key Takeaways

• The Canary Staked INJ ETF (INJC) started trading on Nasdaq on November 5, 2026, giving brokerage investors access to INJ and staking rewards.

• The fund plans to stake at least 90% of its INJ, but it charges a 1.10% sponsor fee and takes a share of the staking rewards.

• Day one volume was very small, so the real test for INJ institutional adoption will be inflows over the coming weeks.

Injective ETF Launch: What Happened on November 5

Nasdaq confirmed it would begin listing the Canary Staked INJ ETF on November 5, with Flow Traders U.S. serving as the designated liquidity provider. The fund's registration became effective a day earlier, clearing the way for trading.

The listing is a change from earlier filings, which pointed to Cboe BZX as the planned venue. Two other INJ related ETF applications are still pending, from 21Shares and REX Osprey.

The Canary Staked INJ ETF in Simple Terms

The Canary Staked INJ ETF is an exchange traded product that gives investors exposure to INJ while adding staking rewards to the fund's value. You buy shares through a regular brokerage account, not a crypto wallet.

Think of it as holding INJ in a managed wrapper. The fund holds the tokens with a custodian and stakes them to help secure the Injective network. Rewards are not paid out as cash. They are reinvested and reflected in the daily net asset value.

How the INJ Staking ETF Works

Custody and Staking

The fund holds INJ directly, and BitGo acts as custodian. Under normal conditions, the sponsor expects to stake at least 90% of the tokens through one or more staking providers.

The rest stays available for redemptions and expenses. That reserve helps the fund meet withdrawals without selling staked tokens in a hurry.

Fees and Injective Staking Rewards

The fund charges an annual sponsor fee of 1.10%. It also expects to keep 30% of staking rewards as a staking fee, leaving 70% for the fund, which then covers sponsor fees and other costs.

So Injective staking rewards in the ETF are lower than staking directly. In exchange, investors get convenience, custody and a familiar trading format.

What the First Day Numbers Show

On debut, INJC opened at about $25.15 and closed near $26.15, with only 2,933 shares changing hands. The fund held roughly 1.91 million INJ, with net assets around $15 million.

That is small next to other recent staking ETF launches. Bitwise's Solana staking ETF saw roughly $56 million in first day volume, and Canary's own XRP ETF saw about $58 million. INJC's first day turnover was in the range of tens of thousands of dollars.

Ready to explore more crypto opportunities? Open a free Bitrue account and access a wide range of digital assets with simple tools designed for every trader.

Why INJ Institutional Adoption Matters

Easier Access

Many funds and advisors cannot hold tokens directly. An ETF removes wallets, private keys and exchange accounts from the picture. That can widen the pool of investors who are able to buy INJ.

Scale Still Small

Context matters, though. INJ has a market cap of around $800 million, and about half of its supply is already staked. The 1.91 million INJ in the fund is a small slice of that supply.

Key Entities Behind INJC

• Injective (INJ): a blockchain built for financial applications, using proof of stake security.

• Canary Capital: the sponsor and issuer of the Canary Staked INJ ETF.

• BitGo: the custodian that holds the fund's INJ.

• Nasdaq: the exchange where INJC trades.

• 21Shares: issuer of AINJ, an INJ staking ETP listed in Europe, with a 2.5% fee.

What It Means for INJ

The listing does not change how Injective works, but it adds a regulated door into the token. Injective has reported more than 3.13 billion transactions and over 7.27 million INJ permanently burned through monthly buybacks, which supports the supply story investors often cite.

A larger group of buyers could add steady demand over time. Staked tokens held by the fund also remove supply from liquid markets. Still, none of this is a guarantee, and price depends on broader market conditions.

Interpretation Cheat Sheet

• NAV: the fund's value per share, based on its INJ holdings and accrued rewards.

• Premium or discount: the gap between the share price and NAV. A small gap signals healthy trading.

• Authorized participants: firms that create and redeem shares. Their activity drives large inflows.

• Volume on debut: a low number shows early caution, not a final verdict on demand.

• Fee drag: sponsor and staking fees reduce what investors keep from rewards.

Risks to Keep in Mind

An ETF share is not the same as owning INJ. You cannot move the tokens to a wallet, vote with them or use them in Injective apps. You also pay fees that direct holders avoid.

Staking carries its own risks too, including network penalties and the time tokens take to unstake. The fund's filing notes that shareholders do not get the protections of regulated futures markets. Crypto prices remain volatile, so only invest what you can afford to lose.

Summary

The Canary Staked INJ ETF marks a real step for Injective. It brings INJ to Nasdaq, packages staking rewards inside the fund, and gives institutions a familiar way to take exposure.

The early signals are mixed. The structure is solid, but first day demand was thin and fees reduce staking yield. The next few weeks of inflows, and the arrival of other INJ ETFs, will show whether this listing becomes a lasting driver for INJ.

Disclaimer: The views expressed belong exclusively to the author and do not reflect the views of this platform. This platform and its affiliates disclaim any responsibility for the accuracy or suitability of the information provided. It is for informational purposes only and not intended as financial or investment advice.

FAQ

What is the Canary Staked INJ ETF?

It is an exchange traded product that holds INJ and stakes it, with net rewards reflected in its daily value. It trades on Nasdaq under the ticker INJC.

When did the INJ ETF start trading?

INJC began trading on Nasdaq on Thursday, November 5, 2026.

Does the INJ staking ETF pay staking rewards to investors?

Not as cash. Rewards are reinvested and show up in the fund's net asset value, after a 30% staking fee and the 1.10% sponsor fee.

How is INJC different from buying INJ directly?

You buy shares in a brokerage account and the fund handles custody and staking. You do not control the tokens, and you pay fund fees.

Will the Injective ETF make the INJ price go up?

No one can promise that. It may widen access and add demand, but day one volume was small, and the price still depends on the wider crypto market.

Disclaimer: The views expressed belong exclusively to the author and do not reflect the views of this platform. This platform and its affiliates disclaim any responsibility for the accuracy or suitability of the information provided. It is for informational purposes only and not intended as financial or investment advice.